FGFR2 and intrahepatic cholangiocarcinoma: Pre-clinical models for FGFR2 fusion-positive ICC have not been widely reported previously although several non-ICC models engineered to express FGFR fusions and FGFR point mutations have be used to investigate therapeutic resistance17,18.